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ABSTRACT
Over the last decade, investigators have developed a
clearer understanding of the genetic alterations underly-
ing thyroid carcinogenesis. A number of biomarkers in-
volvedinthepathogenesisofdifferentiatedthyroidcancer
have undergone intensive study, not only for their role in
tumorigenesis, but also for their potential utility as diag-
nostic and prognostic indicators and therapeutic targets.
This review summarizes the current literature surround-
ing BRAF and its significance in thyroid cancer. Further,
we discuss how molecular analysis can be integrated into
managementalgorithmsforthyroidnodulesandpapillary
thyroid cancer. We also review what is known, to date,
about the association of BRAF and papillary microcarci-
noma as well as using targeted therapies for BRAF as ad-
juvant treatment for metastatic papillary thyroid cancer.
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INTRODUCTION
Papillary thyroid carcinoma (PTC) accounts for the major-
ity of thyroid cancers (85%) and generally carries an ex-
cellent prognosis, with a 10-year survival rate 90% [1].
However,asmallcohortofPTCpatientsgoesontodevelop
recurrent and/or metastatic cancer and ultimately succumb
to the disease. Better methods of identifying and treating
these patients are very much needed. Over the last decade,
an improved understanding of the genetic basis underlying
thedevelopmentofthyroidcancerhasevolvedthatwillun-
doubtedly lead to necessary improvements in the manage-
ment of PTC patients.
It has now been well-established that the development
ofPTCinvolvesactivationofthemitogen-activatedprotein
kinase (MAPK) signaling pathway, which mediates cellu-
lar response to various growth signals. Derangements of
this pathway play a central role in uncontrolled cell prolif-
eration and faulty apoptosis. The BRAF oncogene is a
strongactivatorofthatpathway,andhasbeenimplicatedin
a number of human cancers, including malignant mela-
noma,colorectalcarcinomas,andsarcomas[2].BRAFislo-
catedonchromosome7q24andencodesaserine–threonine
kinase. After activation by RAS, BRAF phosphorylation
triggers a series of activation events along the MAPK cas-
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valine to glutamate (V600E) alteration, leading to constitu-
tive MAPK pathway stimulation. The BRAF V600E muta-
tion is the most common genetic alteration in PTC and has
been reported to occur in up to 80% of papillary thyroid
cancers [4], although most experts quote a prevalence of
45% in PTCs [5]. Nikiforov nicely summarized the role
of BRAF and other key genetic mutations and rearrange-
ments in the pathogenesis of thyroid cancer [3].
Among the various histologic subtypes of PTC, BRAF
V600E mutation is most commonly found in the conven-
tional and tall-cell histologic variants (67%–68% and
80%–83%, respectively), and less commonly found in the
follicular variant (12%–18%) of PTC [6, 7]. BRAF muta-
tions may also occur in thyroid lymphomas and anaplastic
andpoorlydifferentiatedthyroidcancers,buthavenotbeen
identified in follicular or medullary carcinomas and have
onlyveryrarelybeenidentifiedinbenignhyperplasticnod-
ules [8]. Approximately 95% of BRAF mutations involve
V600E[5];otherBRAFmutationshavealsobeenidentified
in PTC, although they are much less common and are not
associated with the same tumor phenotype. Chiosea and
colleagues provide an excellent review of other rare BRAF
mutations that have been reported in the literature [9]. For
the remainder of this article, reference to BRAF is to the
V600E mutation.
BRAF IN THE DIAGNOSIS OF PTC
Fine-needle aspiration biopsy (FNAB) is the gold standard
for the evaluation of thyroid nodules because it is safe,
quick, cost-effective, and accurate [10]. When malignant
cells are seen on cytology, the decision to proceed to sur-
gery is simple, and most experts agree on the extent of ini-
tial thyroidectomy (i.e., near-total or total thyroidectomy)
[11]. However 10%–15% of thyroid nodule FNABs fall
into the indeterminate category, which includes follicular
and oncocytic neoplasms, follicular lesions of undeter-
mined significance, and suspicious nodules, according to
the most current categorization of thyroid nodules estab-
lished by the Bethesda Criteria of the National Cancer In-
stitute [12]. At present, diagnostic thyroidectomy is
recommended to definitively exclude malignancy in pa-
tients with indeterminate lesions. Although the risk is ex-
tremely low in expert hands, thyroid surgery is not without
a risk for complications and carries health care costs. Al-
thoughFNABishighlyaccurateandspecific,anothercom-
plementary diagnostic adjunct is needed to help reduce the
need for diagnostic thyroidectomy and/or better define the
extent of initial surgery. Molecular testing has risen to the
forefront as an exciting focus of research in this area over
the last decade.
AnumberofcentershaverecentlyevaluatedBRAFmu-
tation analysis in the preoperative setting. In a prospec-
tively evaluated Italian cohort of patients with nodules
deemed suspicious sonographically, 48 BRAF
 nodules
were identified after ultrasound-guided FNAB followed by
direct DNA sequencing and restriction fragment length
polymorphism analysis for the BRAF V600E mutation.
Seven patients with benign cytology underwent thyroidec-
tomy because their nodules harbored the mutation, and all
seven had conventional PTC on final histology. The inves-
tigators reported that BRAF mutational analysis increased
the sensitivity of cytology for PTC from 77% to 87% [13].
Jo and colleagues prospectively evaluated 101 thyroid nod-
ules with ultrasound-guided FNAB (43 benign, 30 malig-
nant, 24 indeterminate or suspicious, four nondiagnostic)
and BRAF V600E mutational analysis using pyrosequenc-
ing. Thyroidectomy was performed in 54 patients with ma-
lignant/indeterminate nodules (22 malignant and seven
indeterminate nodules were BRAF
) and one patient with a
nondiagnostic nodule that was BRAF
. All BRAF
 nod-
ules, including the one nondiagnostic and seven indetermi-
nate nodules, were PTC on final histopathology, yielding a
sensitivity of 75% [14]. Xing et al. [15] prospectively eval-
uated 45 patients who had FNA either in the outpatient set-
ting or in the operating room immediately prior to
thyroidectomy; both direct DNA sequencing and a colori-
metric gene detection method were used to carry out BRAF
mutation analysis on the cytology specimens. The sensitiv-
ity, specificity, and negative predictive value (NPV) of
FNAB BRAF testing in that study were 50%, 100%, and
78%, respectively [15]. The same group subsequently eval-
uated FNAB BRAF mutation status as a potential risk strat-
ification tool by correlating mutation status with final
histopathologyandclinicaloutcomesin190PTC(134con-
ventional, 41 follicular variant, 15 tall-cell variant) patients
undergoingtotalornear-totalthyroidectomy.Insomecases
the DNA isolation was from fresh FNAB specimens,
whereas in other cases it was retrospectively obtained from
archived samples. The mutation was identified in 38% of
the PTCs and was a strong predictor of capsular invasion
(p  .05), extrathyroidal extension (p  .04), lymph node
metastasis (p  .002), and tumor persistence/recurrence
(p  .002). In that study, the sensitivity, specificity, posi-
tive predictive value (PPV), and NPV of a BRAF
 FNAB
specimen to predict PTC persistence/recurrence were 68%,
66%, 36%, and 88%, respectively.
AttheUniversityofPittsburgh,since2006wehaverou-
tinely used BRAF testing as part of a panel of molecular
markersusedasadiagnostictooltoimprovetheaccuracyof
FNAB. Nikiforov and his colleagues at the Universities of
Cincinnati and Colorado prospectively evaluated 470
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them for BRAF, RAS, PAX8-PPAR, and RET/PTC muta-
tions, correlating the mutation status results with cytology,
surgical pathology, or clinical follow-up results. TheBRAF
and RAS point mutations were detected using real-time
polymerase chain reaction (PCR) and fluorescence melting
curveanalysis,whereasreversetranscriptionPCRwasused
to detect RET/PTC and PAX8-PPAR rearrangements. In
the study, 97% of mutation-positive nodules were papillary
or follicular carcinoma on final histology. Molecular test-
ingalonehadasensitivityof62%,butwhencombinedwith
cytology, the sensitivity rose to 80% with a PPV of 98%. In
particular, molecular testing was helpful for indeterminate
nodules, with a PPV of 100% for these lesions; 15 of 52
nodules with indeterminate cytology harbored a mutation
and all 15 were malignant on final histology (13 PTC and
twofollicularcarcinoma)[16].Werecentlypublishedaret-
rospective analysis of 44 BRAF
 PTC thyroidectomy pa-
tients who had undergone preoperative BRAF testing on
their FNAB specimens; 31 of the FNAB specimens were
positive (29 PTCs and two inadequate cytological speci-
mens), translating into a sensitivity of 70% [7]. These and
other studies evaluating BRAF testing on FNAB specimens
aresummarizedinTable1.ItisimportanttonoteinTable1
that in both studies that did not report a 100% specificity
and 100% PPV, it was because there was one BRAF
 case
of anaplastic carcinoma [13, 17]. Furthermore, reports
without data to calculate sensitivity, specificity, PPV, and
NPV were excluded from the table [7, 18, 19].
To the best of our knowledge, there have only been six
Table 1. Summary of papers evaluating BRAF testing of FNAB specimens
Study Country Study design
n of PTCs
on final
histopathology
Cytology of confirmed
PTCs Mutation(s) tested
Sensitivity
for PTC
Specificity
for PTC
PPV for
PTC
NPV for
PTC
Bentz et al.
(2009) [51]
USA Retrospective 40 22 PTC, 17
indeterminate, 1 benign
BRAF 42.5% 100% 100% 17.9%
Cantara et al.
(2010) [52]
Italy Prospective 74 46 PTC, 7 indeterminate,
8 benign, 13
nondiagnostic
BRAF
a, RAS, RET,
TRK, PPR
44.6% 100% 100% 79.7%
Cohen et al.
(2004) [17]
USA Retrospective 54 23 PTC, 29
indeterminate, 2 benign
BRAF 32% 97.3% 95.7% 52.9%
Domingues et al.
(2005) [53]
Portugal Prospective 11 9 PTC, 1 indeterminate,
1 benign
BRAF
a, RET/PTC 27.3% 100% 100% 61.9%
Jin et al. (2006)
[25]
USA Retrospective 58 57 PTC, 1 indeterminate BRAF 53.5% 100% 100% 32.5%
Jo et al.
(2009) [14]
Korea Prospective 40 30 PTC, 9 indeterminate,
1 nondiagnostic
BRAF 75% 100% 100% 85.9%
Kim et al.
(2008) [54]
Korea Retrospective 75 57 PTC, 18
indeterminate
BRAF 84% 100% 100% 70%
Marchetti et al.
(2009) [55]
Italy Retrospective 90 56 PTC, 33
indeterminate, 1 benign
BRAF 65.6% 100% 100% 40.4%
Nam et al.
(2010) [56]
Korea Prospective 85 68 PTC, 16
indeterminate or
nondiagnostic, 1 benign
BRAF 71.8% 100% 100% 86.9%
Nikiforov et al.
(2009) [16]
USA Prospective 38 18 PTC, 17
indeterminate, 3 benign
BRAF
a, RAS, RET/PTC,
PAX8/PPAR
47% 100% 100% 70.6%
Ohori et al.
(2010) [24]
USA Prospective 20 20 indeterminate
b BRAF
a, RAS, RET/PTC,
PAX8/PPAR
15% 100% 100% 85.1%
Pizzolanti et al.
(2007) [57]
Italy Prospective 16 13 PTC, 3 indeterminate BRAF
a, RET/PTC 68.8% 100% 100% 86.8%
Rowe et al.
(2006) [58]
USA Retrospective 19 19 indeterminate
b BRAF 15.8% 100% 100% 23.8%
Salvatore et al.
(2004) [59]
Italy Retrospective 69 54 PTC, 11
indeterminate, 4
nondiagnostic
BRAF
a, RET/PTC 37.7% 100% 100% 38.6%
Sapio et al.
(2007) [60]
Italy Prospective 21 21 indeterminate
b BRAF
a, Galectin-3 47.6% 100% 100% 91.8%
Xing et al.
(2004) [15]
USA Prospective 16 10 PTC, 6 indeterminate BRAF 50% 100% 100% 78.4%
Zatelli et al.
(2009) [13]
Italy Prospective 74 45 PTC, 23
indeterminate, 6 benign
BRAF 63.5% 99.7% 97.9% 93.6%
17 Total 800 Average 49.5% 99.8% 99.6% 64.5%
aResults here reflect only BRAF
 specimens, though other mutations were tested in the study.
bThese studies excluded patients with definite cancer on FNAB.
Abbreviations: FNAB, fine-needle aspiration biopsy; NPV, negative predictive value; PPV, positive predictive value; PTC,
papillary thyroid cancer.
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testing. The first report was from Korea, where the BRAF
mutationishighlyprevalent,anddescribesapatientwithan
indeterminate BRAF
 nodule by FNAB who, on final his-
topathology, had atypical hyperplasia in a background of
Hashimoto’s thyroiditis. The authors speculated that the
atypical hyperplasia could have been a precursor lesion for
PTC [20].
More recently, using dual-priming oligonucleotide
(DPO)-based multiplex PCR analysis, which can detect
BRAF V600E in only 2% of cells within a population of
wild-type cells, false-positive BRAF testing occurred in
five of 226 (2%) FNABs. Upon repeat testing of DNA ex-
tracted both from the stored preoperative FNA specimen
and after microdissection of the biopsied nodule, BRAF
mutation was unable to be detected in any of the five nod-
ules, suggesting that the false-positive testing was a result
of the overly sensitive assay. In that study, the overall sen-
sitivityandspecificityofBRAFtestingalonetopredictma-
lignancy were 83% and 99%, respectively. In agreement
with other published studies, the authors concluded that
BRAFtestingimprovedthesensitivityofFNABinpredict-
ing malignancy, although limitations of the testing tech-
niqueshouldalsobeconsideredindeterminingmalignancy
risk [21].
In addition to DPO-based PCR analysis, a number of
othertechniquestodetecttheBRAFmutationhavebeende-
scribed. These include direct sequencing, pyrosequencing,
PCR-based single-strand conformation polymorphism, and
restriction fragment length polymorphism. Depending on
the technique, the tests can detect BRAF V600E if it is
present in 2%–20% of the cells within an otherwise wild-
type background, and the sensitivity, specificity, and PPV
are similar [22, 23]. Regardless of which method for BRAF
mutationdetectionisused,patientsshouldbeappropriately
counseled accordingly. In addition, negative molecular
testing does not eliminate the need for diagnostic thyroid-
ectomy in patients with cytology results in the indetermi-
nate category.
Molecular testing is also proving to be particularly
helpful among thyroid lesions now classified under the
new Bethesda Criteria category of “follicular lesion of
undetermined significance” (FLUS) [12]. Ohori et al.
[24] recently reviewed 100 patients treated at our insti-
tution with 117 FNAB diagnoses of either FLUS or
atypia of undetermined significance, and compared the
results for BRAF, RAS, RET/PTC1, and PAX8-PPAR
testing with those of surgical histopathology. Of the 12
FNAB samples with positive molecular results, three of
12 were BRAF
 and all were PTC on final histopathol-
ogy.TheotherninewerealsoPTCs,butwerepositivefor
other mutations (seven NRAS61, one HRAS61, one
PAX8-PPAR) [24]. Although the current practice for
FLUS FNAB results at our institution is to repeat the
FNAB in short-interval follow-up, molecular testing
may soon direct clinicians when to move directly to di-
agnosticsurgery,aswellastheextentofsurgery(below).
Based on our experience, and after thorough preopera-
tive discussion with consenting patients, we currently
recommend upfront total thyroidectomy for FLUS with
positive mutational analysis results.
The 2009 Revised American Thyroid Association
(ATA) Management Guidelines for Patients with Thyroid
Nodules and Differentiated Thyroid Cancer provide a level
Crecommendationinsupportoftheuseofmolecularmark-
ers to help guide the management of patients with indeter-
minate cytology [11]. Testing for BRAF and other
mutations can be done reliably and reproducibly on already
collected FNAB specimens [25]; however, it is routinely
used in only a handful of centers nationally. The current
data on BRAF testing support its use as a complementary
adjuncttoroutinecytologicanalysis,andwhenpositiveitis
helpful in determining the extent of thyroidectomy for pa-
tients with otherwise indeterminate results. Future cost-
efficacy analyses may provide the driving force for
widespread implementation of preoperative BRAF testing
on thyroid FNA samples, but such analyses must necessar-
ily consider clinical criteria in assessing which groups of
cytology specimens should be tested.
THE PROGNOSTIC UTILITY OF BRAF
Ingeneral,riskstratificationplaysakeyroleinthemanage-
ment of patients with PTC, because patients with high-risk
tumors are treated more aggressively with adjuvant thera-
pies and patients with high-risk tumors undergo more fre-
quent follow-up [11]. A number of risk stratification tools
have been developed, but none have gained universal ac-
ceptance; some risk factors, such as completeness of
resection, can only be assigned postoperatively after his-
topathologicalcharacteristicsbecomeavailable.Theability
to stratify PTC patients into different risk categories preop-
eratively could allow for optimization of the initial surgical
procedure,suchastheextentofthyroidectomy,theaddition
of central compartment lymph node dissection (CCND),
and the extent of lymph node dissection. To date, no risk
stratification classification system is completely accurate,
and additional methods to predict aggressive disease are
needed.
Beyond its strong correlation with PTC, the BRAF
V600E mutation is well described to associate with poor
prognosis [6, 7, 26–28]. Clinicopathologic parameters
established to represent aggressive behavior and poor
1288 BRAF Testing in Papillary Thyroid Cancerprognosis include extrathyroidal extension, multicen-
tricity, local recurrence, lymph node metastasis, and dis-
tant metastases [29, 30]. Lupi et al. [6] evaluated 500
PTCs, of which 43% were BRAF
, and found that pa-
tients with BRAF
 PTC, compared with those with
BRAF
 PTC, had a higher incidence of extrathyroidal
extension, nodal metastasis, multicentricity, and ad-
vancedstage.Kebebewandcolleaguesfollowed314thy-
roid cancer patients for a median of 6 years and found
that the BRAF V600E mutation was independently asso-
ciated with recurrent and persistent PTC by multivariate
analysis [26]. An association between the BRAF V600E
mutation and disease-specific survival has also been
demonstrated. Elisei and colleagues retrospectively
evaluated a small cohort of PTC patients with a median
follow-up of 15 years and observed shorter survival in
the group with BRAF V600E mutation by multivariate
analysis [27]. We recently demonstrated that patients
with BRAF
 PTCs were more likely to require cervical
reoperation than those with BRAF
 PTCs (10% versus
3%; p  .04), even in short-interval follow-up [7]. It is
most likely that a complex “molecular signature” will
one day more precisely identify aggressive PTC, but at
present BRAF is the marker with the greatest prognostic
utility.
ThoughthebodyofliteratureassociatingtheBRAFmu-
tation with poor prognostic features is impressive, some of
the data are retrospective, and BRAF status has not been in-
corporatedintostandardPTCmanagementalgorithmsasof
yet. It remains unclear whether identification of this muta-
tion in isolation, regardless of the presence or absence of
other clinicopathologic characteristics, should prompt cli-
nicianstotreatPTCpatientswithmoreaggressiveadjuvant
therapies and/or closer long-term surveillance. More study
in this regard is required.
BRAF AND PAPILLARY
THYROID MICROCARCINOMA
Papillary thyroid microcarcinoma (PTMC) is defined as
papillary carcinoma 1.0 cm [31]. Although the vast ma-
jorityofPTMCsarelowrisk,uptotwothirdsareassociated
with cervical lymph node metastasis. The disease-specific
mortality rate from PTMC is reportedly up to 2% in some
series [32], and recurrence rates have varied in the range of
3%–17%, depending on the length of follow-up and
whether recurrence was defined biochemically (by thyro-
globulin elevation) or by local recurrence with histopatho-
logic confirmation [33–36]. Because the best management
of patients with PTMC remains very unclear, clinical tools
are urgently required to help identify the small subgroup of
patients with an aggressive tumor and thereby place such
patients into high-risk management algorithms postopera-
tively.
Given what is already known about the significance
of the BRAF V600E mutation in PTC, it is not surprising
that a number of groups have evaluated its prognostic
utility for PTMC. Unlike conventional PTC, for which
the prevalence of the mutation is 45%, the prevalence
of the BRAF mutation in PTMC is somewhat lower, at
30% [28]. A notable exception was seen in a recently
published review of 1,150 Korean patients with PTC by
Park et al. [36]. The frequency of the BRAF V600E mu-
tation was 67.2% in macroPTC, with a comparable fre-
quency of 65.6% among PTMC cases. In addition, they
reported a comparable prevalence between PTC and
PTMC for both extrathyroidal extension (72.4% versus
52.2%) and lymph node metastasis (51.8% versus
34.9%), with mean follow-up times of 53 months and 84
months, respectively [36]. Conversely, Lee et al. [37]
foundthat24of64(38%)PTMCpatientswhounderwent
total thyroidectomy with CCND carried the BRAF
V600E mutation in their tumor; no patient had distant
metastasis, but the BRAF
 cohort had a significantly
higher incidence of extrathyroidal extension (50% ver-
sus 10%; p  .001) and nodal metastasis (50% versus
15%; p  .003). Similarly, Kwak and colleagues evalu-
ated the association of the BRAF V600E mutation with
not only known prognostic factors but also with ultra-
sound characteristics in 339 PTMC patients. On multi-
variate analysis, they found that BRAF mutation was
associated with tumor size, extracapsular invasion, and a
higher tumor–node–metastasis stage. There was no sig-
nificant association with any ultrasound characteristic,
but there was a trend toward an association of BRAF and
marked hypoechogenicity (p  .06) [38]. A study of 214
consecutive Italian patients with classic PTMC found
that 41% of tumors harbored the BRAF V600E mutation
and noted that size, gender, vascular invasion, extrathy-
roidalextension,andmultifocalityshowednosignificant
correlation with BRAF status. However, patients with
BRAF
 tumors were significantly older than those who
didnotharborthemutation(52.7yearsversus33.4years;
p  .001) [39].
To summarize, although these results are not entirely
consistent, we know that a BRAF
 status in PTMC is also
associated with poor clinicopathologic features in most re-
ports, and that may translate into a higher risk for disease
recurrence and shorter survival. Whether patients with
BRAF
 PTMC would benefit from completion thyroidec-
tomy, lymphadenectomy, or radioactive iodine (RAI) abla-
tion remains to be seen. This is a particularly exciting area
of thyroid cancer research because the management of mi-
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clinical practice recommendations based on high-level ev-
idence.
INCORPORATING BRAF STATUS INTO
MANAGEMENT ALGORITHMS
The initial management of PTC is surgical, but in this
area there is much room for improvement. Current ATA
guidelines definitively recommend near-total or total
thyroidectomy for all tumors 1 cm as well as therapeu-
tic neck dissection for patients with clinically positive
central or lateral neck lymphadenopathy [11]. However,
only 20%–30% of indeterminate thyroid nodules harbor
cancer after diagnostic thyroid lobectomy, resulting,
even in the modern era, in many thyroidectomies for
whatprovestobebenignthyroidtissue.Furthermore,pa-
tientsarefrequentlyrequiredtosubmittothedistressand
risks of reoperative completion total thyroidectomy once
the final pathology confirms a carcinoma, and/or must
later undergo reoperative cervical lymphadenectomy.
The ability to identify which PTC patients have aggres-
sive PTC could very usefully allow the surgeon to tailor
the operative approach at initial surgery and also could
potentially provide durable cure.
Because BRAF positivity has clear diagnostic utility
and is an established poor prognostic factor in PTC pa-
tients, we recently evaluated its use for optimizing initial
surgical management, comparing 106 BRAF
 PTC pa-
tients with 100 BRAF
 control patients, all of whom un-
derwentthyroidectomy[7].BRAFtestingoccurredeither
preoperatively on FNAB specimens or on the surgical
specimen. Compared with controls, a higher proportion
of the BRAF
 patients: had suspicious sonographic fea-
tures on preoperative ultrasound (50% versus 33%; p 
.03); underwent total thyroidectomy as the initial surgi-
cal procedure (87% versus 67%; p  .001); had tall-cell
morphology (30% versus 6%; p  .001), extrathyroidal
extension (57% versus 15%; p  .001), lymphovascular
invasion (40% versus 21%; p  .003), and level VI
lymph node metastases (36%versus 12%;p  .003); and
have since required cervical reoperation for persistent or
recurrent disease (10% versus 3%; p  .04). Of the 44
BRAF
 PTC patients who were able to receive preoper-
ative BRAF testing of FNAB specimens, 31 of 44 were
BRAF
, yielding an FNAB detection rate of 70%. FNAB
BRAFtestingwasnegativein13of44cases(30%)inthis
study, largely resulting from either extraction of inade-
quateDNAorFNABofanodulethatwasnottheBRAF

nodule.Onfinalhistopathology,all31patientshadPTC,
including two patients whose FNAB specimens had in-
adequate yield but were BRAF
, yielding an FNAB PPV
of 100%. We further were able to show that, altogether,
preoperative knowledge of a BRAF
 status could have
beneficially altered the initial surgical management in
24% of the 75 PTC patients whose preoperative BRAF
status was either unknown or was falsely negative [7].
Based on these findings, to informed and consenting pa-
tients with BRAF
 cytology we now routinely offer total
thyroidectomy as initial surgery. Similarly, Xing et al.
[19] recently observed a greater than fourfold higher risk
fortumorpersistence/recurrenceamongBRAF
 PTCpa-
tients than among patients with mutation-negative tu-
mors (p  .002), and concluded that BRAF status may be
a useful decision-making tool regarding whether or not
todoaprophylacticcentralcompartmentneckdissection
at initial surgery. Our current management algorithm
for BRAF mutation detected on FNAB is illustrated in
Figure 1.
Figure 1. Management algorithm of papillary thyroid cancer
with a BRAF mutation detected on FNA cytology.
Abbreviations: CCND, central compartment node dissec-
tion; FNAB, fine-needle aspiration biopsy; LN, lymph node;
MRND, modified radical neck dissection; TT, total thyroidec-
tomy.
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initial lymphadenectomy. Proponents of CCND argue
that,althoughthisapproachdoesnotimprovesurvival,it
may decrease the risk for locoregional recurrence and
improve staging accuracy, allowing for a more precise
assessment of the need for postoperative adjuvant ther-
apy [40]. However, these claims have yet to be demon-
strated in the literature, and the benefits of CCND must
verymuchbeweighedagainsttheoften-describedhigher
risks for recurrent laryngeal nerve injury and hypopara-
thyroidism [41]. Because the presence of the BRAF mu-
tationwasassociatedwithcentrallymphnodemetastasis
in the multiple studies already discussed, BRAF testing
may help to delineate which PTC patients should receive
prophylactic CCND at the time of thyroidectomy, espe-
cially because ultrasonography has been shown to be
inaccurate at identifying central compartment lymphad-
enopathy preoperatively [42]. A prospective, random-
ized trial examining this issue would be reasonable and
ethical because true equipoise remains.
BRAF AS A THERAPEUTIC TARGET FOR PTC
The overall 10-year survival rate for patients with differen-
tiated thyroid cancer (DTC) is generally excellent; how-
ever,thereremainsasmallproportionofpatientswhorecur
and/or develop distant metastases and succumb. Treatment
options for this subgroup are limited, and new therapies are
necessary, especially because the mortality from DTC has
not improved in past two to four decades [43]. Given the
prevalence and prognostic significance of the BRAF muta-
tion in PTC, it is an obvious choice for the study of targeted
molecular therapeutic options.
It is hypothesized that one reason why patients with
BRAF
 PTC have a poorer prognosis is because the muta-
tion confers resistance to the conventional adjuvant thera-
pies used to treat PTC. The effectiveness of RAI ablation
for DTC depends on the ability of thyrocytes to take up io-
dide via the sodium-iodide symporter (NIS) located on the
basolateral aspect of the follicular cell membrane. In vitro
studies have documented significantly lower expression
levelsofNISinBRAFV600E
PTCs[44].In2009,Riesco-
Eizaguirreetal.[45]describedanovelmechanismwhereby
BRAF-induced activation of transforming growth factor 
and subsequent activation of the Smad signaling pathway
led to NIS repression in thyroid cancer, a process that their
group had already described in normal thyroid cells. Liu
and colleagues were able to demonstrate, in a human PTC
cell line, the restoration of the expression of several impor-
tant genes involved in iodide metabolism that had previ-
ouslybeensilencedbytheBRAFV600Emutation[46].Ina
recent study by Ricarte-Filho et al. [47], BRAF mutations
were present in a high proportion of RAI-resistant PTC tu-
mors and metastases. BRAF
 PTC may therefore not re-
spond to RAI ablation or thyroid-stimulating hormone
suppression.
A number of BRAF inhibitors have been investigated as
potential new agents for targeted therapies. Perhaps the
agent most familiar to clinical and surgical oncologists is
BAY43–9006, or sorafenib. This potent kinase inhibitor
has activity against a number of tyrosine protein kinases,
including RAF, c-KIT, platelet-derived growth factor, vas-
cular endothelial growth factor receptor (VEGFR)-2, and
VEGFR-3, and has been evaluated in the setting of meta-
staticthyroidcancer.Salvatoreetal.[48]studiedtheeffects
of sorafenib on six thyroid cancer cell lines expressing the
BRAF V600E mutation and found lower proliferation in
cancercellsbutnotinnormalthyroidcells.Themechanism
for sorafenib’s effects is not yet understood, but it does not
appear to be through reinduction of RAI avidity [49]. A re-
cent phase II trial evaluated patients with differentiated
(n  27), medullary (n  1), and poorly differentiated (n 
2) thyroid cancers treated with sorafenib (400 mg twice
daily). Twenty-three percent had a partial response and
53% had stable disease, with an overall median progres-
sion-free survival duration of 79 weeks [50]. A phase III
trialevaluatingitsutilityinrefractorythyroidcanceriscur-
rently in recruitment and the results are highly anticipated.
CONCLUSIONS
The BRAF V600E mutation plays a central role in the
pathogenesis of PTC, prompting further investigation of
BRAF as a diagnostic and prognostic tool. The presence of
a BRAF mutation in an FNAB specimen has a 95% PPV
for PTC, further increasing the sensitivity of an already ac-
curate test. When available, BRAF FNAB testing facilitates
optimal oncologic surgery performed at the initial opera-
tion. Furthermore, BRAF
 PTC tends to be more aggres-
sive, and the mutation should alert clinicians to categorize
patientsaccordinglyashighriskandconsiderpostoperative
adjuvant therapies and more frequent cancer surveillance.
The presence of BRAF is less frequent in papillary micro-
carcinoma and may also be associated with a poorer prog-
nosis. Finally, BRAF as a target for new therapies to treat
high-risk patients with recurrent or metastatic disease who
have exhausted conventional therapies holds exciting
promise.
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